Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Fatty acid metabolism (FAM) is a crucial metabolic characteristic of tumor cells, playing a role in various pathological processes during tumor development. Till now, the prognostic role of FAM-related genes of prostate cancer (PCa) is far from fully investigation. The combinations of 10 machine learning algorithms were applied in this study. A reliable signature, FAM-related gene score (FAMRGs), was developed to predict the prognosis of patients with PCa. External data sets were used to verify the accuracy and robustness of the FAMRGs. Drug sensitivity analysis was used to predict the optimal drug for high-risk PCa patients. The underlying mechanism related to FAMRGs were investigated by functional enrichment analysis. A nomogram based on FAMRGs was developed for personalized prediction of patient prognosis. A stable FAMRGs was construced and validated in 6 independent cohorts. FAMRGs accurately divided PCa patients into low and high risk group. FAMRGs showed stronger predictive ability compared with published prognostic signatures for PCa. Also, the androgen receptor signaling inhibitors (ARSI) treatment response predictive ability of FAMRGs was identified. Five drugs that were most suitable for patients in the high risk group of FAMRGs were screened. It was shown that FAMRGs involved in cell cycle-related pathways. The novel nomogram showed precisely predictive ability for the outcomes of patients with PCa. The FAMRGs can accurately predict the prognosis of PCa patients and is expected to direct the clinical treatment for PCa.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374944PMC
http://dx.doi.org/10.7150/jca.112597DOI Listing

Publication Analysis

Top Keywords

pca patients
12
predictive ability
12
famrgs
11
fatty acid
8
acid metabolism
8
machine learning
8
prostate cancer
8
pca
8
famrgs developed
8
predict prognosis
8

Similar Publications

Stage IV prostate cancer (PCa) refers to a disease that has metastasized beyond the prostate gland to distant sites, such as bones, visceral organs, or non-regional lymph nodes. While early attempts at curative therapy were occasionally made in oligometastatic cases, current guidelines uniformly recommend palliative-intent management once true metastatic spread is confirmed. Over the past decade, treatment paradigms have shifted from androgen deprivation therapy (ADT) monotherapy to earlier intensification with combination regimens including chemo-hormonal therapy and next-generation hormonal agents to improve survival and quality of life (QoL).

View Article and Find Full Text PDF

UHMK1 Promotes Prostate Cancer Progression through a Positive Feedback Loop with MTHFD2.

Oncol Res

September 2025

Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China.

Background: U2AF homology motif kinase 1 (UHMK1) has been associated with RNA processing and protein phosphorylation, thereby influencing tumor progression. The study aimed to explore its regulatory mechanisms and biological functions in human prostate cancer (PCa).

Methods: In this study, we systematically evaluated the expression and prognostic significance of UHMK1 in public databases, followed by validation through immunohistochemistry (IHC) in PCa specimens.

View Article and Find Full Text PDF

Background: Digital therapeutics (DTx) has emerged as a transformative approach in healthcare, offering innovative solutions for disease management and treatment optimization. Prostate cancer (PCa), the second most common malignancy in men, has seen increasing incidence rates, driving the development of new digital technologies for PCa management.

Purpose: This review aims to provide a comprehensive analysis of the current status and effectiveness of DTx in managing PCa.

View Article and Find Full Text PDF

Prostate cancer (PCa) is the most common tumor for men in the genital system. Despite several new therapies approved in the past decades, 34,700 patients die on a regular basis in 2023 in America. Recently radioisotopic therapies have shown the delightful results in the PCa treatment, which made FDA approved lutetium-177 for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer (mCRPC).

View Article and Find Full Text PDF

Clinical, Immunological, and Vesicular Markers in Sarcopenia and Presarcopenia.

Front Biosci (Landmark Ed)

August 2025

Division of Biochemistry and Molecular Biology, Siberian State Medical University, Ministry of Health of the Russian Federation, 634050 Tomsk, Russia.

Background: Sarcopenia is a complex, multifactorial condition characterized by progressive loss of muscle mass, strength, and function. Despite growing awareness, the early diagnosis and pathophysiological characterization of this condition remain challenging due to the lack of integrative biomarkers.

Objective: This study aimed to conduct a comprehensive multilevel profiling of clinical parameters, immune cell phenotypes, extracellular vesicle (EV) signatures, and biochemical markers to elucidate biological gradients associated with different stages of sarcopenia.

View Article and Find Full Text PDF